Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15 17 32
Multi-Infarct Dementia 74 53 71 32
Dementia, Vascular 74 43 71
Vascular Dementia, Susceptibility to 6
Dementia - Multi-Infarct 53
Dementia, Multi-Infarct 43
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 54

Classifications:



External Ids:

Disease Ontology 12 DOID:8725
ICD9CM 34 290.4
SNOMED-CT 67 429998004 56267009
ICD10 32 F01 F01.1 F01.9
UMLS 71 C0011263 C0011269

Summaries for Vascular Dementia

NINDS : 53 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic.

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Folate Metabolism and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Metformin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 74 Vascular dementia (VaD) is dementia caused by problems in the supply of blood to the brain, typically a... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 33.0 NOTCH3 MAPT APP APOE ACHE
2 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 32.4 SERPINA3 NOTCH3 APP APOE
3 dementia 31.8 TNF SERPINA3 RETREG1 PSEN1 PRNP PON1
4 alzheimer disease 31.5 TNF SERPINA3 PSEN1 PRNP PON1 NEFL
5 homocysteinemia 31.2 PON1 MTHFR CST3 APOE
6 vascular disease 31.1 VEGFA TNF PON1 MTHFR IL6 CST3
7 chlamydia pneumonia 31.1 TNF IL6 APOE
8 carotid stenosis 31.0 VEGFA TNF MTHFR APOE ACE
9 lipid metabolism disorder 31.0 PON1 IL6 APOE ACE
10 aphasia 31.0 PSEN1 PRNP MAPT APP APOE
11 alexia 31.0 MAPT BCHE APOE
12 cerebrovascular disease 31.0 TNF SERPINA3 PON1 NOTCH3 MTHFR MAPT
13 arteriosclerosis 30.9 PON1 IL6 CST3 APOE ACE
14 congestive heart failure 30.9 VEGFA TNF IL6 ACE
15 cerebral amyloid angiopathy, cst3-related 30.9 SERPINA3 PSEN1 PRNP MAPT CST3 APP
16 arteriolosclerosis 30.9 SERPINA3 NOTCH3 MAPT APP APOE
17 head injury 30.8 CHAT APOE
18 visual agnosia 30.8 PSEN1 MAPT APOE
19 sleep apnea 30.8 VEGFA TNF IL6 APOE ACE
20 transient cerebral ischemia 30.8 NOTCH3 MTHFR MAPT ACHE
21 temporal arteritis 30.7 TNF SERPINA3 IL6
22 agraphia 30.7 PRNP MAPT ACHE
23 atherosclerosis susceptibility 30.7 VEGFA TNF PON1 MTHFR IL6 APOE
24 coronary heart disease 1 30.7 PON1 MTHFR IL6 APOE ACE
25 anxiety 30.7 TNF IL6 APP APOE ACHE ACE
26 apraxia 30.7 PSEN1 MAPT APOE
27 central nervous system vasculitis 30.7 TNF SERPINA3 IL6
28 peripheral vascular disease 30.7 VEGFA MTHFR IL6 ACE
29 traumatic brain injury 30.7 MBP IL6 APOE
30 sleep disorder 30.6 TNF MAPT IL6 APOE ACE
31 mental depression 30.6 TNF SERPINA3 IL6
32 associative agnosia 30.6 MAPT BCHE
33 frontotemporal dementia 30.6 PSEN1 PRNP NEFL MAPT BCHE APP
34 alzheimer disease 10 30.6 MAPT APOE ACHE
35 nominal aphasia 30.6 MAPT APOE ACHE
36 syphilis 30.6 TNF SERPINA3 IL6 ACE
37 semantic dementia 30.5 PSEN1 MAPT APOE
38 normal pressure hydrocephalus 30.5 VEGFA SERPINA3 PSEN1 MAPT APP APOE
39 amnestic disorder 30.5 PSEN1 MAPT CHAT BCHE APP APOE
40 migraine with or without aura 1 30.5 TNF NOTCH3 MTHFR IL6 APOE ACE
41 major depressive disorder 30.4 VEGFA TNF MTHFR IL6 APOE ACE
42 brain injury 30.4 MBP IL6 APOE
43 bronchopneumonia 30.4 TNF SERPINA3 IL6
44 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 30.4 PSEN1 APP APOE
45 arteriovenous malformation 30.4 VEGFA TNF IL6 APOE
46 carotid artery disease 30.4 PON1 IL6 APOE ACE
47 finger agnosia 30.4 MBP MAPT
48 purpura 30.4 TNF IL6 ACE
49 cerebral atherosclerosis 30.3 SERPINA3 MTHFR APOE ACE
50 creutzfeldt-jakob disease 30.3 SERPINA3 PRNP MAPT CST3 APP APOE

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 ACE ACHE APOE APP CHAT IL6
2 homeostasis/metabolism MP:0005376 10.48 ACE ACHE APOE APP BCHE CHAT
3 growth/size/body region MP:0005378 10.39 ACE ACHE APOE APP CHAT IL6
4 mortality/aging MP:0010768 10.36 ACE ACHE APOE APP BCHE CHAT
5 cardiovascular system MP:0005385 10.35 ACE APOE APP CHAT CST3 IL6
6 cellular MP:0005384 10.34 APOE APP CST3 IL6 MAPT MBP
7 hematopoietic system MP:0005397 10.31 ACE ACHE APOE APP IL6 MAPT
8 integument MP:0010771 10.27 APOE APP IL6 MAPT MTHFR NOTCH3
9 nervous system MP:0003631 10.27 ACHE APOE APP CHAT CST3 IL6
10 immune system MP:0005387 10.25 ACE APOE APP IL6 MAPT MBP
11 muscle MP:0005369 10.21 ACHE APOE APP CHAT CST3 IL6
12 reproductive system MP:0005389 10.03 ACE ACHE APOE APP BCHE CHAT
13 limbs/digits/tail MP:0005371 10.02 APOE CHAT MTHFR PRNP PSEN1 TNF
14 neoplasm MP:0002006 9.95 ACE CST3 IL6 MAPT NOTCH3 TNF
15 no phenotypic analysis MP:0003012 9.92 ACHE APOE APP MAPT MTHFR PRNP
16 normal MP:0002873 9.91 APP CHAT MAPT MBP NEFL NOTCH3
17 respiratory system MP:0005388 9.56 ACHE APOE CHAT IL6 NOTCH3 PSEN1
18 vision/eye MP:0005391 9.4 ACHE APOE CHAT IL6 MAPT MBP

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Galantamine Approved Phase 4 357-70-0 9651
9
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
13
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
14
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
15
Enalaprilat Approved Phase 4 76420-72-9 6917719
16
Doxazosin Approved Phase 4 74191-85-8 3157
17
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
18
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
19
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
22
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
23
Manidipine Approved, Investigational Phase 4 89226-50-6
24
Ramipril Approved Phase 4 87333-19-5 5362129
25
Atenolol Approved Phase 4 29122-68-7 2249
26
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
27
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
28
Choline Approved, Nutraceutical Phase 4 62-49-7 305
29
Candesartan Experimental Phase 4 139481-59-7 2541
30
Corticosterone Experimental Phase 4 50-22-6 5753
31 Insulin, Globin Zinc Phase 4
32 Hypoglycemic Agents Phase 4
33 insulin Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Narcotics Phase 4
36 Analgesics Phase 4
37 Analgesics, Opioid Phase 4
38 Narcotic Antagonists Phase 4
39 Antipyretics Phase 4
40 Neurotransmitter Agents Phase 4
41 Cholinergic Agents Phase 4
42 Protective Agents Phase 4
43 Respiratory System Agents Phase 4
44 Phosphodiesterase 3 Inhibitors Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Fibrinolytic Agents Phase 4
47 Cyclooxygenase Inhibitors Phase 4
48 Vasodilator Agents Phase 4
49 Bronchodilator Agents Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
3 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
4 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
7 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
8 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Completed NCT00640198 Phase 4 memantine;memantine;placebo
9 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
10 A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia Completed NCT01363648 Phase 4 choline alfoscerate;placebo (for choline alphoscerate)
11 Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. Completed NCT00196690 Phase 4 Donepezil
12 Preventing Post-Operative Cognitive Decline Completed NCT00182845 Phase 4 Donepezil
13 Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly Completed NCT00227994 Phase 4 Galantamine;Donepezil
14 Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Completed NCT00741585 Phase 4 Any antihypertensive medication alone or in combination;Any antihypertensive medication alone or in combination
15 Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Recruiting NCT04041349 Phase 4 mouse nerve growth factor
16 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
17 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
18 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
19 Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type Unknown status NCT00190021 Phase 3 donepezil
20 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
21 An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
22 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT00165737 Phase 3 Donepezil Hydrochloride
23 A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
24 A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia. Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
25 A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
26 The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
27 Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial Completed NCT00249158 Phase 3 Risperidone
28 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
29 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia Completed NCT00253123 Phase 3 risperidone
30 Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference Completed NCT00249145 Phase 3 risperidone
31 Serotonergic Pharmacotherapy for Agitation of Dementia Completed NCT00009204 Phase 3 Citalopram [Celexa];Perphenazine [Trilafon]
32 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis Completed NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
33 Ginkgo Biloba Prevention Trial in Older Individuals Completed NCT00010803 Phase 3 Ginkgo biloba;Placebo
34 Effect of Administration of Combination Metformine/Inulin Versus Metformine on Patients With Prostate Benign Hyperplasia and Metabolic Syndrome Syndrome Completed NCT02778776 Phase 3 Metformin
35 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
36 A Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
37 A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia Recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
38 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study Recruiting NCT03785067 Phase 3 telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg;Placebo oral capsule
39 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
40 Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia Active, not recruiting NCT03986424 Phase 3 Akatinol Memantine 20 mg;Akatinol Memantine 10 mg
41 MIND Diet Intervention to Prevent Alzheimer's Disease Active, not recruiting NCT02817074 Phase 3
42 Exercise and Intensive Vascular Risk Reduction in Preventing Dementia Active, not recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
43 An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia Terminated NCT00174382 Phase 3 Donepezil
44 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
45 Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
46 Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia:A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
47 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment Unknown status NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
48 A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Completed NCT02886494 Phase 2 BAC;Matched placebo
49 The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial. Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
50 A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

40
Brain, Testes, Endothelial, Cortex, Heart, Temporal Lobe, Kidney

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 7013)
# Title Authors PMID Year
1
Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. 61 54 6
11273064 2001
2
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. 61 6
15895461 2005
3
Vascular dementia and Alzheimer's disease - are we in a dead-end road? 61 54
20173341 2010
4
Differences between clinical subspecialties in the outpatient evaluation and treatment of dementia in an academic medical center. 61 54
20110698 2010
5
Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. 54 61
19433439 2009
6
Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. 54 61
19359623 2009
7
Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. 54 61
19641318 2009
8
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. 61 54
19221426 2009
9
Choline acetyltransferase activity in vascular dementia and stroke. 61 54
19776575 2009
10
Sporadic vascular dementia as clinical presentation of a new missense mutation within exon 7 of NOTCH3 gene. 54 61
18499132 2008
11
Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. 61 54
18537053 2008
12
Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction. 54 61
18174021 2008
13
Lack of association between apolipoprotein E polymorphism and vascular dementia in Koreans. 61 54
18287165 2008
14
What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia? 54 61
17539949 2007
15
Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. 61 54
17395712 2007
16
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. 54 61
17195931 2007
17
Presenilin gene predisposes to late-onset degenerative but not vascular dementia: a comparative study of PS1 and ApoE genes in a North Indian Cohort. 61 54
17627113 2007
18
Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia. 54 61
17374951 2007
19
Treatment of vascular dementia and vascular cognitive impairment. 61 54
17215726 2007
20
Absence of association between codon 129 and 219 polymorphisms of the prion protein gene and vascular dementia. 61 54
17570906 2007
21
Cortical neuronal apoptosis in CADASIL. 61 54
17008611 2006
22
Diabetes mellitus and dementia. 54 61
17110895 2006
23
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. 54 61
16465461 2006
24
Interventions for heart disease and their effects on Alzheimer's disease. 61 54
16945215 2006
25
Lipid metabolism in cognitive decline and dementia. 61 54
16410024 2006
26
Cognitive frailty: Predementia syndrome and vascular risk factors. 54 61
16023766 2006
27
Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. 54 61
16870640 2006
28
Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. 54 61
16583410 2006
29
[Expression levels of APP and PS1 genes in patients with Alzheimer's disease]. 61 54
16735229 2006
30
Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. 61 54
16555084 2006
31
Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. 61 54
16702784 2006
32
Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? 61 54
16461472 2006
33
Apolipoprotein E epsilon4 allele is associated with vascular dementia. 54 61
16926537 2006
34
Apolipoprotein E epsilon4 allele frequency in vascular dementia. 54 61
16645276 2006
35
Two novel mutations of the NOTCH3 gene in Korean patients with CADASIL. 61 54
16256149 2006
36
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 61 54
15990115 2005
37
CADASIL mutations impair Notch3 glycosylation by Fringe. 54 61
15857853 2005
38
Noninfarct vascular dementia and Alzheimer dementia spectrum. 61 54
15760616 2005
39
Absence of cholinergic deficits in "pure" vascular dementia. 54 61
15642917 2005
40
Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. 54 61
16192723 2005
41
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. 54 61
15677868 2005
42
[The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years]. 54 61
15654671 2004
43
Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. 54 61
15633941 2004
44
[Vascular dementia]. 61 54
15224429 2004
45
Apolipoprotein E polymorphism in ischemic cerebrovascular diseases and vascular dementia patients in Taiwan. 61 54
15084782 2004
46
Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. 61 54
14991454 2004
47
Common polymorphisms in methylenetetrahydrofolate reductase (MTHFR): relationships with plasma homocysteine concentrations and cognitive status in elderly northern italian subjects. 61 54
15207432 2004
48
Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia. 54 61
14739533 2004
49
Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. 61 54
14586274 2003
50
Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. 61 54
14561434 2003

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TNF NM_000594.3(TNF):c.-1037C>TSNV risk factor 12389 rs1799724 6:31542482-31542482 6:31574705-31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 10.01 PSEN1 MTHFR MBP CHAT APP ACHE
2 neuron projection GO:0043005 9.92 PSEN1 NEFL MAPT CHAT APP
3 extracellular space GO:0005615 9.9 VEGFA TNF SERPINA3 PON1 IL6 CST3
4 neuronal cell body GO:0043025 9.89 PSEN1 MBP MAPT CST3 APOE
5 axon GO:0030424 9.85 PSEN1 NEFL MAPT CST3 APP
6 endoplasmic reticulum lumen GO:0005788 9.77 IL6 CST3 BCHE APP APOE
7 growth cone GO:0030426 9.73 PSEN1 NEFL MAPT APP
8 membrane raft GO:0045121 9.72 TNF PSEN1 PRNP MAPT APP
9 blood microparticle GO:0072562 9.71 SERPINA3 PON1 BCHE APOE
10 platelet alpha granule lumen GO:0031093 9.69 VEGFA SERPINA3 APP
11 ciliary rootlet GO:0035253 9.56 PSEN1 APP
12 neuromuscular junction GO:0031594 9.56 PSEN1 NEFL APP ACHE
13 cell surface GO:0009986 9.56 VEGFA TNF PSEN1 PRNP NOTCH3 MBP
14 nuclear envelope lumen GO:0005641 9.55 BCHE APP
15 main axon GO:0044304 9.48 MAPT APP
16 extracellular region GO:0005576 9.44 VEGFA TNF SERPINA3 PON1 NOTCH3 MAPT

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.07 VEGFA TNF PSEN1 IL6 APP
2 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA TNF PSEN1 APP
3 negative regulation of endopeptidase activity GO:0010951 9.89 SERPINA3 PRNP CST3 APP
4 negative regulation of neuron apoptotic process GO:0043524 9.88 RETREG1 PSEN1 NEFL APOE
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 VEGFA TNF IL6
6 neuron projection development GO:0031175 9.85 MAPT IL6 APP APOE
7 cellular protein metabolic process GO:0044267 9.85 PSEN1 IL6 CST3 APP APOE
8 positive regulation of protein binding GO:0032092 9.84 PSEN1 APP ACE
9 forebrain development GO:0030900 9.84 PSEN1 NOTCH3 APP
10 response to glucocorticoid GO:0051384 9.83 TNF IL6 BCHE
11 learning or memory GO:0007611 9.82 PSEN1 PRNP APP
12 positive regulation of MAP kinase activity GO:0043406 9.81 VEGFA TNF PSEN1
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 TNF NOTCH3 IL6
14 response to toxic substance GO:0009636 9.8 PON1 NEFL MBP CST3
15 synapse organization GO:0050808 9.79 PSEN1 MAPT APP
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 VEGFA TNF IL6 APP
17 cellular response to amyloid-beta GO:1904646 9.77 PSEN1 PRNP APP
18 microglial cell activation GO:0001774 9.71 TNF MAPT APP
19 artery morphogenesis GO:0048844 9.69 VEGFA NOTCH3 APOE
20 negative regulation of lipid storage GO:0010888 9.67 TNF IL6
21 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.66 TNF APP
22 axonal transport of mitochondrion GO:0019896 9.65 NEFL MAPT
23 response to oxidative stress GO:0006979 9.65 PSEN1 PRNP CST3 APP APOE
24 response to folic acid GO:0051593 9.64 MTHFR BCHE
25 neutrophil mediated immunity GO:0002446 9.64 IL6 ACE
26 locomotion GO:0040011 9.62 PSEN1 NEFL
27 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.61 PSEN1 APP
28 negative regulation of long-term synaptic potentiation GO:1900272 9.61 PRNP APP APOE
29 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.58 VEGFA ACE
30 amyloid precursor protein metabolic process GO:0042982 9.58 PSEN1 APOE ACHE
31 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.57 PSEN1 APP
32 astrocyte activation involved in immune response GO:0002265 9.56 PSEN1 APP
33 neuron projection maintenance GO:1990535 9.54 PSEN1 PRNP APP
34 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.52 PSEN1 APP
35 modulation of age-related behavioral decline GO:0090647 9.5 PSEN1 PRNP APP
36 negative regulation of gene expression GO:0010629 9.5 VEGFA TNF PSEN1 MAPT APP APOE
37 positive regulation of amyloid fibril formation GO:1905908 9.33 PSEN1 APP APOE
38 astrocyte activation GO:0048143 8.92 TNF PSEN1 MAPT APP

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.56 TNF PRNP MBP CST3
2 growth factor receptor binding GO:0070851 9.4 PSEN1 APP
3 lipoprotein particle binding GO:0071813 9.37 MAPT APOE
4 identical protein binding GO:0042802 9.36 VEGFA TNF PRNP NOTCH3 NEFL MAPT
5 amyloid-beta binding GO:0001540 9.35 PRNP CST3 BCHE APOE ACHE
6 cholinesterase activity GO:0004104 9.32 BCHE ACHE
7 acetylcholinesterase activity GO:0003990 9.16 BCHE ACHE

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....